Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.

BMC pulmonary medicine - 11 Nov 2019

Colombino Maria, Paliogiannis Panagiotis, Cossu Antonio, Santeufemia Davide Adriano, Sini Maria Cristina, Casula Milena, Palomba Grazia, Manca Antonella, Pisano Marina, Doneddu Valentina, Palmieri Giuseppe

Abstract excerpt

BACKGROUND: Lung cancer is one of the most incident neoplastic diseases, and a leading cause of death for cancer worldwide. Knowledge of the incidence of druggable genetic alterations, their correlation with clinical and pathological features of the disease, and their interplay in cases of co-occurrence is crucial for selecting the best therapeutic strategies of patients with non-small cell lung cancer. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to In Situ Hybridization, Fluorescence

Share to Proto-Oncogene Proteins c-met

Share to Proto-Oncogene Proteins p21(ras)

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 31711449
DOI: 10.1186/s12890-019-0964-x
PMCID: PMC6849322

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.PMID 31711449Read ↗

Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies.Semantic proximity Read ↗

Somatic gene mutations and their association with treatment outcomes among Indo-Asian Lung Cancer patients.Semantic proximity Read ↗

Rare molecular subtypes of lung cancer.Semantic proximity Read ↗

Targeting molecular alterations in non-small-cell lung cancer: what's next?Semantic proximity Read ↗

EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.Semantic proximity Read ↗

Lung Adenocarcinoma: Next Generation Sequencing and Outcome in Regional Community Oncology SettingSemantic proximity Read ↗

New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2Semantic proximity Read ↗

Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern SwitzerlandSemantic proximity Read ↗

Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients.Semantic proximity Read ↗

Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan.Semantic proximity Read ↗

Impact of KRASG12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.